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Abstract
Background: High concentrations of glutamate can accumulate in the brain and may be involved
in the pathogenesis of neurodegenerative disorders such as Alzheimer's disease. This form of
neurotoxicity involves changes in the regulation of cellular calcium (Ca2+) and generation of free
radicals such as peroxynitrite (ONOO-). Estrogen may protect against glutamate-induced cell death
by reducing the excitotoxic Ca2+ influx associated with glutamate excitotoxicity. In this study, the
inhibition of N-methyl-D-aspartate (NMDA) receptor and nitric oxide synthase (NOS) along with
the effect of 17β -estradiol (17β -E2) and a more potent antioxidant ∆ 8, 17β -estradiol (∆ 8, 17β -E2)
on cell viability and intracellular Ca2+ ([Ca2+]i), following treatment of rat cortical cells with
glutamate, was investigated.
Results: Primary rat cortical cells were cultured for 7–12 days in Neurobasal medium containing
B27 supplements. Addition of glutamate (200 µM) decreased cell viability to 51.3 ± 0.7% compared
to control. Treatment with the noncompetitive NMDAR antagonist, MK-801, and the NOS
inhibitor, L-NAME, completely prevented cell death. Pretreatment (24 hrs) with 17β -E2 and ∆ 8,
17β -E2 (0.01 to 10 µM) significantly reduced cell death. 17β -E2 was more potent than ∆ 8, 17β -E2.
Glutamate caused a rapid 2.5 fold increase in [Ca2+]i. Treatment with 0.001 to 10 µM MK-801
reduced the initial Ca2+ influx by 14–41% and increased cell viability significantly. Pretreatment with
17β -E2 and ∆ 8, 17β -E2 had no effect on Ca2+ influx but protected the cortical cells against glutamate-
induced cell death.
Conclusion: Glutamate-induced cell death in cortical cultures can occur through NMDAR and
NOS-linked mechanisms by increasing nitric oxide and ONOO-. Equine estrogens: 17β -E2 and ∆ 8,
17β -E2, significantly protected cortical cells against glutamate-induced excitotoxicity by a
mechanism that appears to be independent of Ca2+ influx. To our knowledge, this is a first such
observation. Whether the decrease in NOS related products such as ONOO-, is a mechanism by
which estrogens protect against glutamate toxicity, remains to be investigated. Estrogen
replacement therapy in healthy and young postmenopausal women may protect against
neurodegenerative diseases by these mechanisms.
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Background
A number of neurodegenerative diseases, including Alzhe-
imer's disease (AD) have been proposed to involve a dys-
regulation in the brain's glutamatergic system [1-4]. In
addition, high (mM) glutamate concentrations have been
documented to cause neuronal degeneration in various in
vivo and in vitro models [1]. Although glutamate-induced
cell death is associated with both apoptotic and necrotic
changes [5] the mechanism of cell death remains to be
established.
Two distinct pathways for glutamate-induced cell death
have been described: the excitotoxic pathway and the oxi-
dative pathway. The excitotoxic pathway involves the
overactivation of glutamate receptors that leads to both
rapid and slowly triggered cytotoxic events. The rapid
effects involve the activation of the N-Methyl-D-Aspartate
receptor (NMDAR) that lead to a large Ca2+ influx that
may be detrimental to cell viability [6]. The oxidative
pathway involves the breakdown of the glutamate-cystine
antiporter and a drop in glutathione levels that allows for
aberrant formation of reactive oxygen species (ROS) that
are neurotoxic [7,8].
Although intracellular Ca2+ ([Ca2+]i) is necessary for a
number of physiological processes, excessive amounts
may lead to neuronal dysfunction and cell death. Neuro-
nal increases in Ca2+ can activate a number of enzymes,
such as phospholipases, proteases, endonucleases and
nitric oxide synthase (NOS). Increase in the activity of
these enzymes is associated with neuronal cell death
[9,10]. Excessive glutamatergic stimulation is also associ-
ated with an increase in [Ca2+]i required for neuronal NOS
(nNOS) activation and nitric oxide (NO) production
within the neuron and this can result in increased cell
death [9,11,12]. Therefore, the maintenance of proper
Ca2+ homeostasis may be effective in preventing the pro-
gression of glutamate associated neuronal degeneration.
Previous studies demonstrate that estrogens are neuropro-
tective against the oxidative pathway of glutamate-
induced cell death in a mouse hippocampal cell line,
HT22 [13,14]. This finding, along with other studies
describing estrogen's neuroprotective and neurotrophic
action [13,15,16] support results from observational stud-
ies that exogenous estrogen use by postmenopausal
women is neuroprotective [17-20].
Although estrogens are potent antioxidants [21,22] that
can prevent oxidative damage in cell culture systems,
recent evidence also suggests that estrogen may inhibit
glutamate-induced excitotoxicity [23]. Moreover, estrogen
can lower cytotoxic Ca2+ influxes induced by glutamate in
hippocampal cells [24,25]. Whether this Ca2+ lowering, or
buffering effect occurs in other neuronal cell types, such as
cortical cells, that are known to be estrogen sensitive, and
whether this effect is involved in estrogen's neuroprotec-
tive effects remains to be established.
In this study, the effect of 17β -estradiol (17β -E2) and a
novel ring-B unsaturated equine estrogen with less femi-
nizing effects [26,27] and greater antioxidant potential,
∆ 8, 17β -estradiol (∆ 8, 17β -E2) [21,22] on cell viability and
[Ca2+]i, following treatment of rat cortical cells with gluta-
mate was studied. The concentrations of glutamate used
in the present study are relatively lower than those used in
previous studies where cell death may have occurred
mainly via the oxidative pathway. It is hypothesized that
both estrogens will protect cortical cells from glutamate
induced excitotoxicity by modifying the initial Ca2+ influx
in addition to acting as antioxidants.
Results
Purity of neuronal cultures
Freshly isolated embryonic cortical cells obtained from
day 17–19 pregnant rats were cultured and maintained in
serum-free neurobasal medium containing B27 supple-
ments for 7 days as described under "Materials and Meth-
ods". Phase contrast microscopy indicated that the cells
had characteristic morphology of neurons and their cellu-
lar extensions (dendrites) were clearly visible (Figure 1B).
Immunocytochemistry using anti-rat neuronal specific
enolase (NSE), and anti-glial fibrillary acidic protein
(GFAP) indicates, as can be seen in Figure 1A and Figure
1C, that the cells stained positively only for neuronal eno-
lase (green) while GFAP staining (red) was not detectable.
These data further indicate that almost all cells seen by
phase-contrast microscopy (Figure 1B) were positive for
neuronal enolase (Figure 1A). Thus, the cultures used in
our studies are purely neuronal.
Effect of glutamate on cell viability
Cortical neuronal cells (4 × 104) cultured for 7 days in 96-
well plates were treated with increasing concentrations
(0.1 to1000 µM) of glutamate for 20 min and cell viability
was measured after 24 hrs and compared with vehicle-
treated samples. As depicted in Figure 2, 0.1 to 5 µM gluta-
mate resulted in minimal cell death. As the amount of
glutamate increased between 5 to 100 µM, the cell death
increased gradually in a dose-dependent manner. Thus,
treatment with 10 µM glutamate and 50 µM glutamate
decreased cell viability by 35.6  ± 3.6% and 54 ± 2.5%
respectively. Higher concentrations (>50 µM) of gluta-
mate did not result in any further decrease in cell viability
(Figure 2). Thus cell death induced by acute glutamate
treatment reached a plateau in these rat primary cortical
cells with concentrations of glutamate between 50 and
1000 µM. For all subsequent experiments 200 µM gluta-
mate was used to induce cell death and this concentration
resulted in a mean cell death of 48.7 ± 0.7%.BMC Neuroscience 2005, 6:34 http://www.biomedcentral.com/1471-2202/6/34
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Kinetics of glutamate-induced cell death
In order to determine the kinetics of glutamate excitotox-
icity, rat primary cortical neurons were cultured for 7 days
and then treated with 200 µM glutamate for 20 min. Cell
death was then assessed at 2, 4, 8, and 24 hrs as described
under "Materials and Methods".
The results depicted in Figure 3 indicated that acute gluta-
mate treatment resulted in a time-dependent increase in
LDH release compared to vehicle treated cells. Measure-
ment of LDH release at 2 hours resulted in no observable
difference in LDH release compared to vehicle treated
samples, however after 4 hours, an increase in LDH
release of 13 ± 2.7% (p < 0.05) compared to control was
observed. At 8 hours LDH release increased by 40 ± 6.8%
(p < 0.05) over control. No significant increase in LDH
release was observed thereafter (Figure 3). The change in
LDH release ratio between glutamate and the control cells
at 8 hours (40 ± 6.8%) compared to 24 hrs (42 ± 3.4%)
was not statistically significant. Thus, it appears that the
majority of cell death in rat primary cortical cells from
acute glutamate exposure occurred between 2 to 8 hours
post glutamate treatment.
Effect of estrogen on glutamate-induced cell death
To determine whether the neurotoxic effect of glutamate
can be prevented by estrogen treatment, cells were pre-
treated for 24 hrs with various concentrations, 0.01 to 10
µM, of 17β -E2 or ∆ 8, 17β -E2, glutamate treatment was then
initiated and cell viability was measured after 24 hrs. An
acute (20 minute), 200 µM glutamate exposure resulted in
a 50% decrease in cell viability. As depicted in Figure 4,
pretreatment with 17β -E2 or ∆ 8, 17β -E2 for 24 hrs resulted
in a dose-dependent increase in cell viability against gluta-
mate-induced neurotoxicity. No significant protection
was observed with 0.01 to 0.05 µM 17β -E2, however, 0.1
to 5 µM 17β -E2 resulted in a 8.16 ± 1.93% to 20.94 ±
2.13% increase in protection (p < 0.05) respectively. Sim-
ilarly, pretreatment with 0.01 to 0.5 µM  ∆ 8, 17β -E2
resulted in an increase in protection from 0.63 ± 1.74% to
6.85 ± 2.09% respectively, however, statistical significance
at these concentrations was not reached. In contrast, pre-
treatment with 1 and 5 µM ∆ 8, 17β -E2 resulted in a signif-
icant (p < 0.05) increase in protection of 9.24 ± 2.23%
and 12.12 ± 2.11% respectively (Figure 4). Higher concen-
tration (10 µM) of both estrogens did not result in any fur-
ther increase in protection. Although both 17β -E2 and ∆ 8,
17β -E2 were able to significantly reduce the glutamate-
induced cell death complete protection was not achieved
with the concentrations tested. However, the results do
indicate that 17β -E2  was more effective in preventing
glutamate-induced cell death than ∆ 8, 17β -E2 (Figure 4)
and this was found to be significant with the 0.1 to 10 µM
concentrations of estrogen tested (p < 0.05). Pretreatment
of cells with estrogen for 15 minutes did not protect the
cells against glutamate neurotoxicity, (data not shown).
Immunocytochemistry for neuron specific enolase (NSE) (green) and glial fibrillary acidic protein (GFAP) (red) Figure 1
Immunocytochemistry for neuron specific enolase (NSE) (green) and glial fibrillary acidic protein (GFAP) 
(red). Cortical cells were grown in serum-free Neurobasal medium supplemented with 2% B27 for 7 days prior to dual stain-
ing and visualization with fluorescence and phase contrast microscopy. Images shown were taken at 300× magnification. All 
images are taken from the same field of view. A. Fluorescence image of cortical cells stained for NSE. Arrowheads represent 
cells stained positive for NSE. B. Phase contrast image of cortical cells. C. Fluorescence image of cells stained for GFAP. Note 
almost all cells in (B) stain positive for NSE (A) and no cells stain positive for GFAP (C) indicating absence of glia.
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Effect of NMDA and NOS inhibitors on glutamate-induced 
cell death
To determine whether the neurotoxic effect of acute gluta-
mate treatment on rat primary cortical neurons is medi-
ated through the NMDAR or NO, cell viability was
determined following inhibition of NMDAR function or
inhibition of NOS activity in cells treated acutely with 200
µM glutamate. As can be seen in Figure 5, a 20 minute
exposure with 200 µM glutamate in rat primary cortical
cells resulted in a 44.43 ± 1.34% decrease in cell viability
compared to the vehicle treated control (p < 0.001). A 15
minute pretreatment with 0.1 µM MK-801, a non-specific
antagonist of the NMDAR, completely prevented cell
death (p < 0.001) compared to glutamate alone treated
samples. Similarly, a 15 minute pretreatment with 10 mM
NOS inhibitor L-NAME also completely prevented the cell
death induced by glutamate (p < 0.001) compared to
glutamate alone treated samples. These results clearly
indicate that cell death induced by glutamate involves
both NMDAR and NO.
Effect of glutamate on intracellular calcium levels
To evaluate the effect of glutamate on [Ca2+]i concentra-
tions in cortical neurons various glutamate concentra-
tions, (0.1 to 200 µM), were added to wells and changes
in relative fluorescence units (RFU) were recorded. Base-
line readings were taken every 15 seconds for a total of 60
seconds prior to an injection (10 µl) of glutamate into
each well (indicated by glu Figure 6A). Readings were con-
tinued for another 2 minutes post-injection. The kinetics
of glutamate induced Ca2+ influx are depicted in Figure
6A, and as can be seen, glutamate treatment (Figure 6A)
results in a rapid increase in [Ca2+]i with all concentrations
of glutamate (0.1 to 200 µM) tested. This initial rapid rise
in [Ca2+]i occurs at 15 seconds after glutamate addition
and is followed by a reduced rate of Ca2+ influx. The
Effect of glutamate on cell viability Figure 2
Effect of glutamate on cell viability. Neuronal cells were maintained for 7 days in conditions similar to those described 
under Figure 1. Cells were treated with various concentrations of glutamate for 20 mins. Cell viability was determined 24 hrs 
later. Untreated control consisted of cells exposed to Lockes buffer only. Each treatment was repeated 8 times. Error bars 
represent SEM.
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kinetics of glutamate-induced Ca2+ influx following the
initial rise in [Ca2+]i remain relatively stable, but are ele-
vated at glutamate concentration between 0.1 and 1 µM.
However, at higher glutamate concentration (5 to 200
µM), [Ca2+]i continues to increase following the initial rise
in [Ca2+]i. In addition, glutamate treatment results in a
dose dependent increase in the initial rise in [Ca2+]i levels
measured at 15 seconds, and reaches significance (p <
0.05) with 0.5 µM to 200 µM glutamate (Figure 6B). Max-
imal [Ca2+]i levels were observed with 10 µM glutamate
and further increase in glutamate concentration did not
result in any further increase in [Ca2+]i (Figure 6B).
Effect of NMDAR antagonist, MK-801, on glutamate-
induced Ca2+ influx
In order to evaluate the contribution of glutamate-
induced Ca2+ influx on cell viability the effect of NMDAR
antagonist MK-801 on Ca2+ influx and cell viability was
measured 24 hours later in the same cell population after
glutamate treatment. The maximum initial Ca2+ influx
was reached 15 seconds after glutamate (200 µM) injec-
tion and percent of maximum initial Ca2+ influx was cal-
culated for each concentration of MK-801 (0.001 to 10
µM). As can be seen in Figure 7, a 15 minute pretreatment
with 0.001 to 10 µM MK-801 resulted in a significant
dose-dependent reduction in the initial (15 seconds) Ca2+
influx by 14.17 ± 2.56% to 40.30 ± 2.28% respectively.
Thus, between 0 µM and 10 µM MK-801, the concentra-
tion of [Ca2+]i drops from an initial high level of 350 nM
Kinetics of glutamate-induced cell death Figure 3
Kinetics of glutamate-induced cell death. Neuronal cells were maintained for 7 days in conditions similar to those 
described under Figure 1. Cells were treated with 200 µM glutamate for 20 mins. LDH release was measured at 2, 4, 8 and 24 
hrs later. Results are expressed as percent LDH increase from control values. Each point is an average of 8 replicates. Error 
bars represent SEM.
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(glutamate alone) at 15 seconds to 200 nM (glutamate
+10 µM MK-801). This drop in Ca2+ influx was associated
with a dose-dependent increase in cell viability compared
to glutamate alone (Figure 8). MK-801 mediated
protection reached significance (p < 0.05) with 0.01 µM
MK-801 and 0.1 µM - 10 µM MK-801, completely pre-
vented glutamate-induced cell death (Figure 8).
Effect of estrogen on glutamate-induced calcium influx
The effect of estrogen on acute, glutamate (200 µM)
induced Ca2+ influx was measured at various concentra-
tions (0.01 to 10 µM) of 17β -E2 and ∆ 8, 17β -E2. Represent-
ative traces for the effect of 5 µM 17β -E2 and ∆ 8, 17β -E2 on
the glutamate-induced Ca2+ influx are presented in Figure
9. Baseline [Ca2+]i measurements were made every 15 sec-
onds for a total of 60 seconds and measurements were
continued every 15 seconds following glutamate addition
(indicated by glu in Figure 9). As shown in Figure 9, prior
to glutamate addition [Ca2+]ilevels were below 20 nM and
remained relatively constant. Addition of 200 µM gluta-
mate resulted in an immediate increase in concentration
of [Ca2+]i to levels above 300 nM (Figure 9A and 9B). Pre-
treatment with 5 µM 17β -E2 or ∆ 8, 17β -E2 was not associ-
ated with any significant decrease in the levels of [Ca2+]i
induced by glutamate (Figures 9A and 9B). However,
pretreatment with estrogens resulted in a significant (p <
0.05) but modest increase (up to 20%) in cell protection
compared to glutamate alone. Similarly, no effect on the
initial glutamate induced Ca2+ influx was observed at all
other concentrations (0.01 to 1 µM) of estrogen. These
Effect of estrogen on glutamate-induced cell death Figure 4
Effect of estrogen on glutamate-induced cell death. Neuronal cells were maintained for 6 days under conditions similar 
to those described under Figure 1. Cells were treated with various concentrations of 17β -E2 and ∆ 8, 17β -E2. After 24 hrs cells 
were treated with 200 µM glutamate for 20 mins. Cell viability was measured 24 hrs later. Results are expressed as increase in 
percent protection compared to glutamate alone. Solid bars represent 17β -E2. Hatched bars represent ∆ 8, 17β -E2. a. p < 0.05, 
between glutamate alone and estrogen treatment. b. p < 0.05, between 17β -E2 and ∆ 8, 17β -E2. Each experiment was repeated 
a minimum of 6 times with 8 replicates per experiment. Error bars represent SEM.
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results indicate that protection against glutamate-induced
cell death in rat primary cortical neuronal cells by
estrogen does not involve a reduction in the glutamate-
induced, NMDAR associated, Ca2+ influx, and thus estro-
gen mediated protection appears to be mediated by a Ca2+
independent mechanism.
Discussion
In this study, we demonstrate that in primary cultures of
pure rat embryonic cortical neurons, acute (20 min) treat-
ment with glutamate results in a dose and time-dependent
cell death. Over 50% of cells die at a glutamate concentra-
tion of 50 µM. Higher concentrations (> 50 µM) of gluta-
mate did not result in any further increase in cell death.
These findings are in keeping with previous observations
with cultures of purified embryonic rat spinal cord motor
neurons where NMDA and non-NMDA glutamate recep-
tor agonists kill a maximum of 40% of the neurons [28].
In contrast to these findings some studies with
immortalized hippocampal cells (HT22) cultured in
media containing serum have reported glutamate-
induced cell death to occur only at concentrations in the
millimolar range [8,13,14]. Taken together, these findings
suggests that the cell type and culture conditions may play
an important role in the sensitivity of cells towards gluta-
mate-induced cell death. In addition, a main difference
between rat primary cortical neuronal cells and the HT22
cells used, is that the HT22 cells are devoid of functional
NMDARs and thus the cell death induced in these cells at
Effect of MK-801 and L-NAME on glutamate-induced cell death Figure 5
Effect of MK-801 and L-NAME on glutamate-induced cell death. Neuronal cells were maintained for 7 days in condi-
tions similar to those described under Figure 1. Cells were treated with either 0.1 µM MK-801 or 10 mM L-NAME. After 15 
mins cells were then treated with 200 µM glutamate. Results are expressed as percent of control. a. p < 0.05 compared to con-
trol. b. p < 0.05 compared to glutamate alone treatment. Each bar represents a mean of 8 replicates. Error bars represent SEM.
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high concentrations of glutamate is thought to proceed
mainly through the oxidative pathway rather than the
excitotoxic pathway [7,8].
Although the primary cortical neurons used in our study
are sensitive to small changes in glutamate concentrations
(0.1 to 50 µM), the extent of neuronal death under our
experimental conditions (50%) is lower than that
reported in a number of studies where mixed cell cultures
containing neuronal, glial and other cell types were used.
In these mixed cultures over 85% of motor neurons died
following treatment with glutamate [29,30]. It has further
been demonstrated that in such mixed cell cultures,
glutamate receptor agonists may induce cell death by acti-
vating receptors on the susceptible neurons or by activat-
ing receptors in non-neuronal cells. This results in the
release of substances such as NO that are toxic to neurons
[31,32]. Thus, the lower extent (50%) of cell death
observed in cultures maintained in neurobasal medium
containing B27 supplements is most likely due to the high
purity (absence of glia) of the neuronal cultures used in
our study. The absence of glia in our neuronal cultures
(Figure 1) maintained in serum free neurobasal medium
and B27 supplements has also been reported in a number
of earlier studies [16,23,33,34].
Alternatively, it is also possible that the lower extent of cell
death after a short (20 min) exposure to excitotoxic levels
of glutamate (200 µM) may be due to the presence of
glutamate sensitive and insensitive neurons in our
Effect of time and concentration of glutamate on [Ca2+]i Figure 6
Effect of time and concentration of glutamate on [Ca2+]i. Neuronal cells were maintained for 7 days in conditions sim-
ilar to those described under Figure 1. Cells were loaded with 5 µM Fluo-3 AM and treated with various concentrations of 
glutamate. Changes in fluorescence were monitored using the Fluorskan Ascent FL and results were converted to changes in 
[Ca2+]i (nM) as described in the materials and methods. A. [Ca2+]i measurements were made every 15 secs. Baseline levels of 
[Ca2+]i were monitored for 60 secs prior to injection with various concentrations of glutamate (indicated by glu). Following 
injection changes in [Ca2+]i were monitored for an additional 120 secs. B. Initial peak [Ca2+]i change measured at 15 secs post 
glutamate injection. Each point/bar represents a mean of 8 replicates. Error bars represent SEM.
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cultures and this has also been reported by others
[23,28,35]. It has further been demonstrated in pure
motor neuronal cultures (7 day old) that survival (60%)
of a subset of neurons treated with glutamate was unlikely
to be due to the lack of differential glutamate receptor
expression [28]. These authors further suggest that
selective vulnerability may be down stream of the rise in
intracellular Ca2+ that occurs after treatment with gluta-
mate or agonists [28].
Previous studies, in particular with mixed cortical cultures
or spinal cord neurons, have indicated that the age or mat-
uration of neurons is important in the extent of neuronal
death following treatment with glutamate. Thus, in mixed
18 day old cultures of neurons, glutamate treatment
resulted in over 80% neuronal cell death compared to
only 25% cell death in 4 day old cultures [36]. Since we
have used cortical neurons that have been maintained in
culture for only 7 days, it is possible that the extent of neu-
ronal cell death induced by glutamate may further
increase in longer-term cultures. Although we have been
able to maintain some neurons for longer periods than
one week, these neurons, even in the absence of
glutamate, continue to die at variable rates. In keeping
with our observations, Fryer et al [28] reported that 95%
of pure motor neurons in culture die by 7 days. It appears
Effect of various concentrations of MK-801 on glutamate-induced [Ca2+]i influx Figure 7
Effect of various concentrations of MK-801 on glutamate-induced [Ca2+]i influx. Neuronal cells were maintained for 
7 days in conditions similar to those described under Figure 1, prior to loading with 5 µM Fluo-3 AM. After a 15 min treatment 
with various concentrations of MK-801 cells were treated with 200 µM glutamate. Changes in fluorescence were monitored 
using the Fluorskan Ascent FL and results were converted to changes in [Ca2+]i (nM) as described in the materials and meth-
ods. [Ca2+]i measurements were recorded every 15 secs. Baseline levels of [Ca2+]i were monitored for 60 secs prior to injec-
tion with 200 µM glutamate (indicated by glu). Following injection changes in [Ca2+]i were monitored for an additional 120 secs. 
MK-801 (0 µM) represents 200 µM glutamate alone treatment. Each point represents a mean of 8 replicates. Error bars repre-
sent SEM.
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that long-term cultures of pure neurons maintained in
absence of serum cannot at present be used to address the
question of the effect of glutamate on neurons main-
tained in culture for extended periods of time.
The kinetics of glutamate-induced cell death indicated
that while an acute (20 minute) exposure to glutamate
was sufficient to cause cell death, cell death did not occur
until 4 to 8 hours following glutamate treatment. This
delay in cell death is suggestive of apoptosis. Indeed,
recent evidence indicates that apoptotic mechanisms can
play an important role in glutamate-induced neuronal cell
death [13,14,37-40]. Thus, we have demonstrated in
HT22 mouse hippocampal cells that glutamate induced
apoptosis was associated with DNA fragmentation, mor-
phological changes and up-regulation of the pro-apop-
totic protein Bax and down-regulation of the anti-
apoptotic protein Bcl-2. Moreover, this process was
reversed by estrogens [14]. We have further shown that in
primary cortical neurons glutamate-induced apoptosis by
caspase-3 dependent and independent mechanisms
involves mitochondrial release of cytochrome C and
Effect of MK-801 on glutamate-induced cell death Figure 8
Effect of MK-801 on glutamate-induced cell death. Cell viability was determined in the same cells used for experiments 
described in Figure 7 and is expressed as percent of control. Cells were pretreated for 15 minutes with various concentrations 
of MK-801 (0.001 to 10 µM) and then treated for 20 minutes with 200 µM glutamate. a. p < 0.05 compared to glutamate alone. 
Each bar represents a mean of 8 replicates. Error bars represent SEM.
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apoptosis inducing factor (AIF) and these apoptotic
changes were reversed by equine estrogens [37].
While the mechanism of glutamate-induced cell death has
not been fully elucidated, results from the present study
clearly indicate that glutamate-induced cell death in
primary cortical cells is NMDAR and NOS linked. The
relatively short time required for glutamate to initiate the
cell death process and the requirement for NMDAR
activation and NO production, suggest that this cell death
is primarily excitotoxic. These findings are in keeping with
previous observations that suggest excitotoxic cell death in
cortical cultures is dependent on NMDAR and NOS activ-
ity [11,12]. Furthermore, it has been suggested that it is
the production of ONOO- from increased NO formation
that may be responsible for cell death and that this
increase in NO is dependent on NMDA associated Ca2+
influx [9]. Therefore, reduction in Ca2+ influx or NO pro-
duction are two potential mechanisms by which neuro-
protective agents may act.
The data from the present study clearly indicates that
estrogen can protect against glutamate-induced excitotox-
icity in primary cortical cells and a 24 hour pretreatment
prior to glutamate insult is sufficient to provide this pro-
tection. In a previous study [23] protective effects of 17β -
E2 were observed at physiological concentrations, while
the concentrations we used were pharmacological. The
Effect of estrogen treatment on glutamate-induced [Ca2+]i and cell death Figure 9
Effect of estrogen treatment on glutamate-induced [Ca2+]i and cell death. Neuronal cells were maintained for 6 
days in conditions similar to those described under Figure 1. Cells were treated with various concentrations of 17β -E2 and ∆ 8, 
17β -E2. After 24 hrs cells were loaded with 5 µM Fluo-3 AM and then treated with 200 µM glutamate. [Ca2+]i measurements 
were made every 15 secs. Baseline levels of [Ca2+]i were monitored for 60 secs prior to injection with 200 µM glutamate (indi-
cated by glu). Following injection changes in [Ca2+]i were monitored for an additional 120 secs. A. Representative trace of the 
effect of 5 µM 17β -E2 on glutamate-induced [Ca2+]i influx. Inset. Increase in percent protection with 5µM 17β -E2 against 200 
µM glutamate-induced cell death (same cells as those in which [Ca2+]i measurements were made). B. Representative trace of 
the effect of ∆ 8, 17β -E2 on glutamate-induced [Ca2+]i influx. Inset. Increase in percent protection with 5 µM ∆ 8, 17β -E2 against 
200 µM glutamate-induced cell death (same cells as those in which [Ca2+]i measurements were made). Each experiment was 
repeated a minimum of 6 times with 8 replicates of each treatment condition per experiment. Error bars represent SEM.
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differences are most likely due to culture conditions used:
their media [23] contained antioxidants, higher cell den-
sity and lower glutamate concentrations. Since estrogens
are potent antioxidants [21,22], the presence of other
antioxidants in the media may explain the differences
between our findings and those reported previously [23].
Although the concentrations of estrogen used in our study
are high, significantly high levels [70 ng/hr/mL] were
found in postmenopausal women taking a single
therapeutic dose of conjugated equine estrogen [41].
Whether the levels used in the present study are attained
in women taking these estrogens daily for extended peri-
ods of time remains to be determined.
It has been previously suggested that the antioxidant
property of estrogen may be one possible mechanism by
which estrogens exert their neuroprotective activity.
Therefore, if estrogen mediated neuroprotection occurs
solely through an antioxidant mechanism, then ∆ 8, 17β -
E2 (a more potent antioxidant estrogen) [21,22,42] would
be expected to be much more effective in preventing gluta-
mate-induced cell death than 17β -E2. However, in the
present study 17β -E2 was significantly more potent than
∆ 8, 17β -E2. The difference in neuroprotective potency sug-
gests that the protective effect under the experimental con-
ditions used in the present study are not solely dependent
on the estrogen's antioxidant potency. The difference may
also be due to the experimental design used in the present
study (ex in vivo versus whole cell). Although ∆ 8, 17β -E2 is
less potent than 17β -E2, its use as a potential neuroprotec-
tive agent warrants further investigation. This estrogen is a
weaker uterotropic estrogen than 17β -E2 and its effects
appear to be mediated mainly via the estrogen receptor β
(ERβ ) [26,27,43]. Thus, ∆ 8, 17β -E2 may have therapeutic
applications in both women and men for prevention of
neurodegeneration. Whether this neuroprotection also
occurs through the well characterized genomic mecha-
nism involving ERs (ERα  and ERβ ) or through the
putative membrane receptor pathways [44] remains to be
investigated.
As we have shown, glutamate-induced excitotoxicity is
dependent on NMDAR activity and therefore, changes in
Ca2+ influx across the cell membrane may trigger mecha-
nisms involved in cell death [6]. Indeed, it was observed
in the present study that following glutamate stimulation,
a rapid dose-dependent increase in [Ca2+]i occurs that is
associated with a dose-dependent decrease in cell
viability. However, stimulation with glutamate above 10
µM did not further increase [Ca2+]i again suggesting that
glutamate insensitive and sensitive cells may have been
present in these primary cortical cultures.
The observation that glutamate-induced Ca2+  influx
decreased significantly by MK-801 suggests that this to
some extent occurs via NMDAR. Increasing concentra-
tions of MK-801 resulted in a gradual lowering of the
[Ca2+]i concentration within 15 seconds after glutamate
treatment. Thus MK-801 (10 µM) reduced the [Ca2+]i from
350 nM to 200 nM in 15 seconds (Figure 7). Although the
fall in [Ca2+]i levels between 0.01 to 0.1 µM MK-801 was
less than 5% (270 nM to 260 nM respectively; Figure 7),
the cell viability increased from 58% to 100%, (Figure 8).
These types of glutamate-induced small changes in [Ca2+]i
that result in large (total) and significant cell death of cor-
tical/glial cell cultures have been previously observed
[45]. These investigators explained this by suggesting the
presence of a critical Ca2+ "threshold". They further sug-
gested that even a small reduction in NMDA receptor acti-
vation may be sufficient to reduce Ca2+ influx below this
critical threshold such that neural cell death is signifi-
cantly reduced. Our results (Figures 6,7,8) indicate that
perhaps such a threshold may also be present in pure neu-
ronal cortical cells.
In the present study the effect of estrogen on excitotoxic
Ca2+ influx was investigated and although 17β -E2 and ∆ 8,
17β -E2 both provided significant protection (Figure 9),
neither had any effect on the glutamate-induced
Ca2+influx contrary to our working hypothesis. Thus it
appears that the estrogen mediated protection of primary
cortical cells from acute glutamate exposure does not
involve a decrease in the glutamate-induced Ca2+ influx,
and to our knowledge this is a first such observation. In
contrast to these findings a previous study in hippocam-
pal cells cultured in media containing antioxidants, has
shown that estrogen can reduce the glutamate-induced
Ca2+ influx by increasing mitochondrial sequestration of
Ca2+ [25]. This increased sequestration was attributed to
the ability of estrogen to increase Bcl-2, an antiapoptotic
protein that is important in mitochondrial Ca2+ sequestra-
tion [46,47]. Whether estrogen modulates Bcl-2 expres-
sion in primary cortical cells in a manner similar to our
previous study with HT22 cells [14] or whether mitochon-
drial sequestration of Ca2+ occurs remains to be estab-
lished. Furthermore, these investigators [25] cultured the
hippocampal cells in medium that contained antioxi-
dants and this may also explain some of the differences
observed. Our results do however, indicate that the mech-
anism by means of which MK-801 and estrogens protect
against glutamate-induced cell death, appears to be differ-
ent. Further studies are needed to identify these
differences.
There are many other effects of estrogen on the central
nervous system that have been described, for example,
estrogen can alter NOS expression throughout the brain
and potentially upregulate antioxidant proteins through
cyclic guanosine monophosphate linked mechanisms
[48,49]. Such alterations may play a role in glutamateBMC Neuroscience 2005, 6:34 http://www.biomedcentral.com/1471-2202/6/34
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excitotoxicity by affecting subsequent events in the cell
death pathway, downstream of the initial Ca2+ influx. In
addition, the rapid activation of mitogen-activated pro-
tein kinase (MAPK) by estrogen has been shown to be nec-
essary for estrogenic protection although how and what
the function of MAPK is in preventing cell death remains
to be established [50]. Similarly, the phosphorylation of
CREB (cAMP [cyclic adenosine monophospate] response
element-binding protein) and upregulation of
neurotrophic factors such as brain-derived neurotrophic
factor [51], may play a role in neuronal protection [52].
Whether these factors are involved in prevention of gluta-
mate-induced excitotoxicity by equine estrogens remains
to be determined.
Conclusion
Glutamate-induced cell death in cortical cultures occurs
through NMDAR and NOS-linked mechanisms, presuma-
bly through elevated [Ca2+]i levels that activate NOS and
increase the levels of NO and subsequently ONOO-free
radicals. Equine estrogens, 17β -E2 and ∆ 8, 17β -E2, signifi-
cantly protect against glutamate-induced excitotoxicity
through a mechanism that is independent of Ca2+. This is
to our knowledge a first such observation. Whether a
decrease in NOS related products, such as ONOO-, may
be one mechanism by which estrogen provides neuropro-
tection against glutamate toxicity, remain to be
investigated.
Methods
Isolation and culture of cortical cells
Day 17–19 pregnant Sprague Dawley rats were anesthe-
tized and sacrificed by cervical dislocation. The fetuses
were delivered, decapitated and the brains were dissected
out. Each cortex was isolated and individual cells were cul-
tured essentially according to Brewer et al [33,34] with the
following modifications. Briefly, the tissue was main-
tained in Hank's balanced salt solution (HBSS)
(Invitrogen, Life Technologies, Burlington, ON, Canada)
until enough tissue to give sufficient cell numbers for plat-
ing was collected. The tissue was then dispersed by
mechanical dissociation through a series of constricted
fire polished, siliconized Pasteur pipettes to obtain a sus-
pension of single cells. The suspension was then centri-
fuged and the cells were washed to remove red blood cells
and other impurities. An aliquot was stained with 4%
trypan blue, live cells were counted using a hemocytome-
ter and the suspension was then diluted accordingly with
neurobasal defined medium (Invitrogen, Life Technolo-
gies, Burlington, ON, Canada) supplemented with 2% of
B27 containing antioxidants (Invitrogen, Life Technolo-
gies, Burlington, ON, Canada), 0.5 mM glutamine, peni-
cillin G (10 U/mL) and streptomycin (13 µg/mL)
purchased all from Sigma, Canada. This medium was
labeled as neurobasal complete (NBC).
Cells, 40,000 per well, were seeded onto poly-D-lysine
coated 96 well plates (BD Biosciences, Discovery Labware,
Bedford, MA, USA) and were maintained in NBC. Under
these culture conditions, it has been previously demon-
strated (16,23,33,34) that only neurons survive while glia
are essentially absent. The purity of our cortical neuronal
cultures is described separately. After day 1 of plating the
media was completely replaced and on subsequent days
50% of the media was replaced. Cell cultures were main-
tained for 7–12 days at which time glutamate experiments
were initiated. Preliminary experiments carried out during
the standardization of the methods indicated that the cell
viability decreased and was variable after day 7 in culture.
Although some neurons were viable up to day 12, all
experiments described in the manuscript were carried out
in cultures maintained for only 7 days.
Detection of neuronal specific enolase (NSE) and glia-
specific glial fibrillary acid protein (GFAP) by 
immunocytochemistry
Cortical cells on poly-D-lysine coated plates were cultured
in NBC medium as described above. After seven days, cells
were washed twice with PBS and then fixed with 4% for-
maldehyde in PBS for 15 minutes. Cells were then washed
three times with PBS and non-specific binding was
blocked for 5 mins with PBS containing 1% BSA (Sigma,
Canada), 5% normal goat serum (Sigma, Canada), 0.05%
Triton-X100 (BDH, Canada). Cells were incubated for 2
hrs at room temperature with rabbit anti-rat neuron spe-
cific enolase (anti NSE; Polyscience, PA, USA) 1:1000
dilution in block solution. After rinsing 4 times with PBS,
the cells were incubated at room temperature with Alexa
Fluor 488 F(ab')2 fragment of goat anti-rabbit IgG (H+L)
secondary antibody (Molecular Probes, Invitrogen, Can-
ada) 1:400 dilution in block solution. Cells were then
rinsed 4 times with PBS and the fluorescence labeling was
visualized and photographed using Olympus IMT-2
microscope, equipped with a mercury light source and
spot slider digital camera (Diagnosis Instruments, MI,
USA). The neuronal cells displayed characteristic green
fluorescence (Figure 10A).
The neuronal cells maintained in NBC are devoid of glial
cells and to obtain cultures containing glia, the cortical
cells were prepared as described above but were main-
tained in Dubelcco's Modified Eagle Medium (DMEM,
Sigma Canada) containing 10% Fetal Bovine Serum (FBS;
Invitrogen Canada Inc; On, Canada). After 7 days in cul-
ture, the mixture of cells were processed for immunocytol-
ogy by incubating with the primary antibody mouse anti-
GFAP (1:4000 dilution; Sigma Canada) and then with
Texas Red dye conjugated AffiniPure F (ab')2 fragment
goat anti-mouse IgG (H+L) (1:100 dilution; Jackson
Immunoresearch Laboratories, PA, USA) as described
above for NSE, (data not shown). The GFAP positive glialBMC Neuroscience 2005, 6:34 http://www.biomedcentral.com/1471-2202/6/34
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cells stain red as seen in Figure 10B. For double staining,
cells maintained in NBC medium were first incubated
with primary and secondary antibodies for GFAP and after
rinsing four times with PBS, the cells were incubated with
antibodies for NSE. Cells were then visualized and photo-
graphed. The dual staining indicated that the cells were
only positive for neuronal NSE and negative for glial
GFAP (Figure 1A and 1C).
Treatment of cells
For determination of the effect of glutamate on the viabil-
ity of rat primary cortical cells, the cells were washed twice
with a modified Locke's buffer (154 mM NaCl, 5.6 mM
KCl, 3.6 mM NaHCO3, 2.3 mM CaCl2, 5.6 mM Glucose,
5 mM HEPES, 10 µM Glycine, pH 7.4) and incubated for
24 hours at 37°C and 5% CO2 in NBC medium, plus 0.5
mM glutamine and 2% B27 minus antioxidants (NBC
AO-). Following this, the cells were washed 3 times with
modified Locke's buffer and glutamate exposure was initi-
ated. All glutamate treatments were conducted in modi-
fied Locke's buffer. Various concentrations of glutamate
were added to a final concentration of 0.1, 0.5, 1, 5, 10,
50, 100, 200, 500 and 1000 µM for a total of 20 minutes
and changes in [Ca2+]i were recorded. The cells were then
washed with modified Locke's buffer and NBC AO- was
added and cells were incubated at 37°C, 5% CO2 for 24
hours, following which cell death/viability was measured.
Measurement for Ca2+ and cell death/viability were per-
formed on the same culture of cells.
The kinetics of glutamate-induced cell death following a
20 minute exposure to glutamate was also measured using
a concentration of glutamate found to be toxic to 50% of
the cells. Cell death measurements were made at 2, 4, 8
and 24 hours post glutamate treatment and comparisons
between glutamate treated samples and vehicle (modified
Locke's buffer) treated samples were made.
For the determination of the effects of estrogen on gluta-
mate induced changes, cells were washed twice with mod-
ified Locke's buffer and then fresh NBC AO- and estrogens
were added to final concentrations of 0.01, 0.05, 0.1, 0.5,
1 and 10 µM and the cells were incubated for 24 hours at
37°C and 5% CO2. Estrogens were dissolved in ethanol
and diluted to working concentrations with NBC AO-
medium. The final concentration of ethanol was 0.2% for
control and estrogen treated samples. Following incuba-
tion with estrogen and prior to glutamate exposure cells
were prepared for [Ca2+]i  measurements as outlined
below. The cells were washed and incubated in Locke's
buffer containing sufficient (200 µM) glutamate (pre-
determined) to give 50% cell death. Incubations were
Detection of NSE (green) and GFAP (red) by immunocytochemistry in neurons and glia Figure 10
Detection of NSE (green) and GFAP (red) by immunocytochemistry in neurons and glia. Cells were labelled with 
either anti-NSE or anti-GFAP and visualized by fluorescence microscopy. Neuronal cells were grown in Neurobasal medium 
supplemented with 2% B27 and maintained for 7 days in culture. Glial cells were grown in DMEM supplemented with 10% Fetal 
Bovine Serum and maintained for 7 days in culture. (A) Neurons labelled with anti-NSE. (B) Glial cells labelled with anti-GFAP. 
Images were taken at 300× magnification.
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carried out at 37°C for 20 minutes and changes in [Ca2+]i
were recorded. Following glutamate treatment cells were
washed with fresh Locke's buffer and NBC AO- was
added. The cells were again incubated for 24 hours at
37°C and 5% CO2, following which cell viability was
determined.
In some experiments various concentrations of MK-801,
an NMDAR antagonist, and 10 mM of L-NAME [53], a
NOS inhibitor, were added 15 minutes prior to glutamate
exposure following which changes in [Ca2+]i and cell via-
bility were measured.
Evaluation of cell death and viability
The Lactate dehydrogenase (LDH) cytotoxicity assay
(Promega G1780, VWR, Toronto, Ontario, Canada) and
the CellTiter 96® AQueous Non-Radioactive cell prolifera-
tion assay (MTS method) (Promega G5430) were used to
assess cell death and viability respectively. The LDH assay
measures the amount of lactate dehydrogenase that is
released from dead cells while the MTS method measures
the formation of a formazan product in live cells. Changes
in optical density (O.D.) at 490 nm were measured using
the SpectraMax 340 microplate reader and SOFTmax®
PRO software (Molecular Devices, California, U.S.A.) and
comparisons of treated to control values were made. Both
of these methods provide a reliable measure of cell death/
viability.
Measurement of intracellular calcium levels
Intracellular Calcium levels were assessed using the fluo-
rescent probe Fluo-3 AM (Molecular Probes, Eugene, OR,
USA). Changes in relative fluorescence units (RFU) were
monitored with the Fluoroskan Ascent FL fluorescent
plate reader equipped with a micro-injection syringe
pump (Labsystems, Helsinki, Finland). The protocol for
intracellular dye loading was based on the method pro-
vided by the manufacturer (Molecular Probes and Labsys-
tems Fluo-3 AM Application Note) with minor
modifications. Briefly, cells were loaded with 5 µM Fluo-
3 AM for 2 hours and then washed three times with
Locke's buffer to remove excess dye. Cell plates were then
placed in the Fluoroskan and incubated for an additional
15 minutes at 37°C to allow for complete de-esterifica-
tion of dye. Measurements of relative fluorescence units
(RFU) were made using an excitation and emission wave-
length of 485 and 527 nm respectively. Change in [Ca2+]i
(nM) was calculated by multiplying the ratio of ∆ F-Fmin
and Fmax-∆ F by Kd. Where ∆ F is the change in RFU, Fmax
is the maximum observed RFU following NP40 treatment,
Fmin is the minimum observed RFU following EGTA Ca2+
chelation and Kd is the dissociation constant for Fluo-3
AM, 390 nM, provided by supplier (Molecular Probes).
Data analysis
The dose-response curves for effects of glutamate and
estrogen on cell viability and [Ca2+]i were developed using
Slide Write Plus V6 Software (Advanced Graphics
Software, Inc., Encinitas, CA) using the non-linear curve
fitting functions. Each estrogen experiment was carried
out a minimum of six times with eight replicates per treat-
ment condition and all values shown in figures are the
mean ± standard error of the mean (SEM). All treatment
conditions were compared to the respective controls and
an effect was determined significant if p < 0.05. All statis-
tical analyses were performed using Instat®  Software
(Graph Pad, San Diego, CA). To establish the effect of
estrogen against glutamate induced cell death and [Ca2+]i,
nonparametric statistical analyses were performed using
the Kruskal-Wallis nonparametric analysis of variance test
with the Dunn post hoc test to compare each estrogen
concentration against the glutamate alone control.
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